Speed and Cumulative Responses According to Body Regions in Patients with Moderate-to-Severe Plaque Psoriasis Treated with Ixekizumab (Interleukin-17A Antagonist) versus Guselkumab (Interleukin-23p19 Inhibitor)

Speed and Cumulative Responses According to Body Regions in Patients with Moderate-to-Severe Plaque Psoriasis Treated with Ixekizumab (Interleukin-17A Antagonist) versus Guselkumab (Interleukin-23p19 Inhibitor)

Abstract Introduction When assessing the effect of a therapy for psoriasis (PsO), it is important to consider speed of response and cumulative response. However, responses among biologics may differ by body regions. This post hoc analysis compares speed of response and cumulative response for ixekiz...

Full description

Bibliographic Details
Main Authors: Melinda Gooderham, Ronald Vender, Jeffrey Crowley, H. Chih-Ho Hong, Meghan Feely, Alyssa Garrelts, Kyoungah See, Bruce Konicek, Lawrence Green
Format: Article
Language:English
Published: Adis, Springer Healthcare 2024-02-01
Series:Dermatology and Therapy
Subjects:
Body regions
Cumulative response
Ixekizumab
IXORA-R
Moderate-to-severe plaque psoriasis
PASI
Online Access:https://doi.org/10.1007/s13555-023-01075-y

Internet

https://doi.org/10.1007/s13555-023-01075-y

Similar Items